Pricing and Market Access Archives - Pharmaceutical Technology

India sees insignificant revision to price ceiling in 2024

Leyla Hasanzadeh — Tue, 16 Apr 2024 09:00:35 +0000

Lenmeldy becomes world’s most expensive drug

Aman Bansal — Tue, 02 Apr 2024 13:19:33 +0000

The gene therapy for MLD, Lenmeldy (also branded as Libmeldy in some markets), has become the most expensive drug on the market.

Defining the HTA landscape for France and Germany: 2019–2023

Alex Watt — Mon, 18 Mar 2024 15:56:55 +0000

Using GlobalData’s POLI & HTA database, analysis has been conducted that will provide insight into how the HTA landscape adapted between 2019 and 2023.

Panama updates their medicine regulatory system

Daniela Morales — Fri, 01 Mar 2024 17:14:06 +0000

Panama’s government expects to be a pioneer in the area through the centralisation of drug procurement with an emphasis on pharmacovigilance.

HHS advocates for health equity through sickle cell initiative

Akosua Mireku — Thu, 29 Feb 2024 16:40:27 +0000

The US HHS Secretary called for state collaboration on a project to improve gene therapy access for sickle cell disease.

Japan’s FY 2024 pricing reform expected to favour new listed innovative drugs

Chia Lin — Thu, 15 Feb 2024 12:29:46 +0000

In 2023, Japan approved the outlines of its drug pricing and repricing reform for NHI-listed drugs that will take effect in FY 2024 and FY 2025.

Healthcare providers favour pricing control as US drug costs soar

Akosua Mireku — Thu, 01 Feb 2024 15:32:20 +0000

GlobalData reports that HCPs predict a continued increase in drug prices, as inflationary pressures rise.

Germany’s Ministry of Health refutes accusations of worsening market conditions

Brendan Melck — Wed, 31 Jan 2024 15:32:53 +0000

Germany’s Federal Ministry of Health has published its evaluation report on the impact of the GKV Financial Stabilization Act on access to medicines.

EU access to oncology medicines lags behind in the Netherlands

Alex Watt — Wed, 17 Jan 2024 13:01:46 +0000

In a report, findings suggested that cancer patients in the Netherlands will face longer waits to access new oncology medicines.

Patching the problem of EU drug shortages

Eoin Ryan — Wed, 20 Dec 2023 15:39:57 +0000

The EU’s “Union list of critical medicines” stole many pharma-related headlines this week. Its publication is significant, but the impact has been overblown in some quarters.